Engineered immune cells take on Hard-to-Treat cancers
NCT ID NCT05003895
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The study includes 38 adults with advanced solid tumors, such as liver cancer, who have not responded to prior treatments. Participants receive chemotherapy followed by a single infusion of the modified cells and are monitored closely for safety and any tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cells targeting GPC3
- What this could lead to
- If successful, this could point toward a new treatment option for advanced liver cancer and other solid tumors that express GPC3.
- What could go wrong
- This is an early Phase 1 trial with only 38 participants, so safety and dosing are still being tested. The treatment may not shrink tumors or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?